Archives of Gynecology and Obstetrics

, Volume 298, Issue 5, pp 911–920 | Cite as

A prospective cohort study on the prediction of the diagnosis-to-delivery time in preeclamptic pregnancies: should the sFlt-1/PlGF ratio be added to routine evaluations?

  • Semir KoseEmail author
  • Gamze Tuna
  • Gülnar Nuriyeva
  • Sabahattin Altunyurt
  • Gül Hüray Islekel
  • Omer Erbil Doğan
Maternal-Fetal Medicine



To analyze the clinical and laboratory factors that potentially affect the diagnosis-to-delivery time in preeclamptic pregnancies.


In this cross-sectional study, we followed 24 early onset preeclampsia (E-PE) and 26 late-onset preeclampsia (L-PE) cases. Maternal serum samples were obtained at the time of diagnosis and stored at − 80 °C until ELISA analysis for soluble fms-like tyrosine kinase-1 (SFlt-1) and placental growth factor (PlGF) levels.


The median follow-up duration was 68 (1–339) h in the E-PE group and 330 (7–1344) h in the L-PE group. Maternal mean arterial pressure (MAP) at hospitalization was the strongest variable, and the sFlt-1/PlGF ratio added significantly to the Cox regression model. In the E-PE cases, the median sFlt-1/PlGF ratio was significantly higher in the subgroup with a follow-up duration > 48 h than in the subgroup of cases with a follow-up duration ≤ 48 h (5109 vs. 2080; p = 0.038), and none of the seven cases with an sFlt-1/PlGF ratio ≥ 75th percentile delivered during the first 48 h. Neither the 24-h proteinuria nor the gestational age at diagnosis added to the predictive power of the MAP at hospitalization.


Incorporation of the sFlt-1/PlGF ratio to the routine evaluation of preeclamptic pregnancies may help in the prediction of progression and management planning.


Diagnosis-to-delivery time Preeclampsia Placental growth factor Soluble fms-like tyrosine kinase sFlt-1/PlGF ratio 


Author contributions

SK: involved in protocol development, data collection, data analysis, and manuscript writing; GT: laboratory analysis and data collection; GN: protocol development and data collection; SA: protocol development and manuscript editing; GHI: laboratory analysis and manuscript editing; OED: protocol development and manuscript editing.


This research was supported by a grant from Dokuz Eylul University Scientific Research Projects Coordination Unit.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ (2016) Pre-eclampsia. Lancet 387:999–1011CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Chaiworapongsa T, Chaemsaithong P, Korzeniewski SJ, Yeo L, Romero R (2014) Pre-eclampsia part 2: prediction, prevention and management. Nat Rev Nephrol 10:531–540CrossRefPubMedCentralGoogle Scholar
  3. 3.
    American College of Obstetricians and Gynecologists’ (ACOG) (2013) American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy: hypertension in pregnancy. Obstet Gynecol 122:1122–1131CrossRefGoogle Scholar
  4. 4.
    National Institute for Health and Clinical Excellence (2010) Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. Accessed 1 Jan 2018
  5. 5.
    Churchill D, Duley L, Thornton JG, Jones L (2013) Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation. Cochrane Database Syst Rev 7:CD003106Google Scholar
  6. 6.
    Publications Committee, Society for Maternal-Fetal Medicine, Sibai BM (2011) Evaluation and management of severe preeclampsia before 34 weeks’ gestation. Am J Obstet Gynecol 205:191–198CrossRefGoogle Scholar
  7. 7.
    Wang Y, Hao M, Sampson S, Xia J (2017) Elective delivery versus expectant management for pre-eclampsia: a meta-analysis of RCTs. Arch Gynecol Obstet 295:607–622CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Redman CW, Sargent IL, Staff AC (2014) IFPA senior award lecture: making sense of pre-eclampsia- two placental causes of preeclampsia? Placenta 35:S20–S25CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA (2012) Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125:911–919CrossRefPubMedCentralGoogle Scholar
  10. 10.
    ACOG Committee on Obstetric Practice (2002) ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 77:67–75CrossRefGoogle Scholar
  11. 11.
    Locatelli A, Zagarella A, Toso L, Assi F, Ghidini A, Biffi A (2004) Serial assessment of amniotic fluid index in uncomplicated term pregnancies: prognostic value of amniotic fluid reduction. J Matern Fetal Neonatal Med 15:233–236CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Liu Y, Zhao Y, Yu A, Zhao B, Gao Y, Niu H (2015) Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Arch Gynecol Obstet 292:507–518CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Bahlmann F, Al Naimi A (2016) Using the angiogenic factors sFlt-1 and PlGF with Doppler ultrasound of the uterine artery for confirming preeclampsia. Arch Gynecol Obstet 294:1133–1139CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Gómez-Arriaga PI, Herraiz I, López-Jiménez EA, Escribano D, Denk B, Galindo A (2014) Uterine artery Doppler and sFlt-1/PlGF ratio: prognostic value in early-onset pre-eclampsia. Ultrasound Obstet Gynecol 43:525–532CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H (2012) The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 206:58.e1–58.e8CrossRefGoogle Scholar
  16. 16.
    McKinney D, Boyd H, Langager A, Oswald M, Pfister A, Warshak CR (2016) The impact of fetal growth restriction on latency in the setting of expectant management of preeclampsia. Am J Obstet Gynecol 214:395.e1–395.e7CrossRefGoogle Scholar
  17. 17.
    Chen Q, Shen F, Gao YF, Zhao M (2015) An analysis of expectant management in women with early-onset preeclampsia in China. J Hum Hypertens 29:379–384CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Zhao M, Zhu Z, Liu C, Zhang Z (2017) Dual-cutoff of sFlt-1/PlGF ratio in the stratification of preeclampsia: a systematic review and meta-analysis. Arch Gynecol Obstet 295:1079–1087CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649–658CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Mooney SS, Lee RM, Tong S, Brownfoot FC (2016) Expectant management of severe preterm preeclampsia: a comparison of maternal and fetal indications for delivery. J Matern Fetal Neonatal Med 29:3821–3826CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Pilliod RA, Feinberg BB, Burwick RM (2016) Maternal and feto-placental phenotypes of early-onset severe preeclampsia. J Matern Fetal Neonatal Med 29:1209–1213CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Onda K, Tong S, Nakahara A, Kondo M, Monchusho H, Hirano T, Kaitu’u-Lino T, Beard S, Binder N, Tuohey L, Brownfoot F, Hannan NJ (2015) Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction:potential therapeutic for preeclampsia. Hypertension 65:855–862CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Brownfoot FC, Tong S, Hannan NJ, Hastie R, Cannon P, Tuohey L, Kaitu’u-Lino TJ (2015) YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: a possible therapeutic for preeclampsia. Mol Cell Endocrinol 413:202–208CrossRefPubMedCentralGoogle Scholar
  24. 24.
    Brownfoot FC, Hastie R, Hannan NJ, Cannon P, Tuohey L, Parry LJ, Senadheera S, Illanes SE, Kaitu’u-Lino TJ, Tong S (2016) Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol 214:356.e1–356.e15CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Perinatology, Department of Obstetrics and GynecologyDokuz Eylul University School of MedicineIzmirTurkey
  2. 2.Department of Molecular MedicineDokuz Eylul University Institute of Health SciencesIzmirTurkey
  3. 3.Department of Medical BiochemistryDokuz Eylul University School of MedicineIzmirTurkey

Personalised recommendations